Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Sorafenib in De Novo AML
NCT01371981Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2011
- Primary completion
- Mar 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 5
01
Overview
A Phase 3 trial of bortezomib, sorafenib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jul 2011; status: completed.
02
Drugs
bortezomibsorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01371981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371981.